Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2006 6
2007 1
2008 3
2012 2
2013 2
2014 17
2015 41
2016 47
2017 37
2018 36
2019 13
2020 7
2021 6
2022 8
2023 11
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Showing results for ye tong shang
Your search for Yetong Shang retrieved no results
Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.
Wang X, Yang X, Zhang C, Wang Y, Cheng T, Duan L, Tong Z, Tan S, Zhang H, Saw PE, Gu Y, Wang J, Zhang Y, Shang L, Liu Y, Jiang S, Yan B, Li R, Yang Y, Yu J, Chen Y, Gao GF, Ye Q, Gao S. Wang X, et al. Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6640-6650. doi: 10.1073/pnas.1921445117. Epub 2020 Mar 11. Proc Natl Acad Sci U S A. 2020. PMID: 32161124 Free PMC article.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Progression of Vascular Calcification and Clinical Outcomes in Patients Receiving Maintenance Dialysis.
Zhang H, Li G, Yu X, Yang J, Jiang A, Cheng H, Fu J, Liang X, Liu J, Lou J, Wang M, Xing C, Zhang A, Zhang M, Xiao X, Yu C, Wang R, Wang L, Chen Y, Guan T, Peng A, Chen N, Hao C, Liu B, Wang S, Shen D, Jia Z, Liu Z; China Dialysis Calcification Study Group. Zhang H, et al. JAMA Netw Open. 2023 May 1;6(5):e2310909. doi: 10.1001/jamanetworkopen.2023.10909. JAMA Netw Open. 2023. PMID: 37126347 Free PMC article.
Expert consensus on the use of omalizumab in chronic urticaria in China.
Zhao Z, Cai T, Chen H, Chen L, Chen Y, Gao X, Gao X, Geng S, Guo Y, Hao F, Hao G, Hu Y, Jin H, Jin Z, Li C, Li H, Li J, Li Y, Liang Y, Liu G, Liu Q, Long H, Ma L, Shang Y, Song Y, Song Z, Su X, Sui H, Sun Q, Sun Y, Tang J, Tong X, Wang H, Wang G, Wang L, Wang S, Xiang L, Xiao T, Xie Z, Ye L, Yu Y, Zhang C, Zhang L, Zhang S, Zheng R, Zhi L, Zhou W, Zou Y, Maurer M. Zhao Z, et al. World Allergy Organ J. 2021 Dec 5;14(11):100610. doi: 10.1016/j.waojou.2021.100610. eCollection 2021 Nov. World Allergy Organ J. 2021. PMID: 34934470 Free PMC article. Review.
DeepFundus: A flow-cytometry-like image quality classifier for boosting the whole life cycle of medical artificial intelligence.
Liu L, Wu X, Lin D, Zhao L, Li M, Yun D, Lin Z, Pang J, Li L, Wu Y, Lai W, Xiao W, Shang Y, Feng W, Tan X, Li Q, Liu S, Lin X, Sun J, Zhao Y, Yang X, Ye Q, Zhong Y, Huang X, He Y, Fu Z, Xiang Y, Zhang L, Zhao M, Qu J, Xu F, Lu P, Li J, Xu F, Wei W, Dong L, Dai G, He X, Yan W, Zhu Q, Lu L, Zhang J, Zhou W, Meng X, Li S, Shen M, Jiang Q, Chen N, Zhou X, Li M, Wang Y, Zou H, Zhong H, Yang W, Shou W, Zhong X, Yang Z, Ding L, Hu Y, Tan G, He W, Zhao X, Chen Y, Liu Y, Lin H. Liu L, et al. Cell Rep Med. 2023 Feb 21;4(2):100912. doi: 10.1016/j.xcrm.2022.100912. Epub 2023 Jan 19. Cell Rep Med. 2023. PMID: 36669488 Free PMC article.
The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
Wei Q, Tan Y, Xu P, Tao E, Lu Z, Pan X, Wang B, Liu C, Dong X, Tian Y, Sun X, Cattaneo C, Chen S, Shang H; XINDI Study Investigators Group. Wei Q, et al. CNS Drugs. 2022 Nov;36(11):1217-1227. doi: 10.1007/s40263-022-00958-6. Epub 2022 Nov 8. CNS Drugs. 2022. PMID: 36346534 Free PMC article. Clinical Trial.
245 results